Cell death

Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Positive

Retrieved on: 
Thursday, April 18, 2024
Community, Diagnosis, Civil service commission, Ovarian cancer, Cell death, Prevalence, Cell division, Disease, Clinical, Patient, Committee, EMA, IRIS, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of ovarian cancer in the European Union on 9 December 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • Upifitamab rilsodotin is composed of an antibody that binds NaPi2b and a drug called AF-HPA which prevents cell division, resulting in cell death.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Medigene AG Secures European Patent for its iM-TCR Technology

Retrieved on: 
Thursday, April 4, 2024
TCR, Patent, CSO, Research, Cell death, European Patent Convention, Safety

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies.
  • “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage.
  • Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research and experience.
  • We are pleased to receive this latest patent grant for our iM-TCR technology from the European Patent Office, which complements our recently granted patent in Japan,” said Dolores Schendel, CSO at Medigene.

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
WEE1, Medication, Research, 2D, Cell death, DNA repair, Colorectal cancer, Patient, SAN, DNA, Cell cycle, 3D, Lung cancer, AACR, Cancer, Poster, Therapy, Pharmaceutical industry

Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.

Key Points: 
  • Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.
  • Our preclinical data demonstrate that combining azenosertib with KRASG12C inhibitors dramatically enhances anti-tumor activity.
  • The research that will be presented at AACR Annual Meeting 2024 evaluated the anti-tumor activity of azenosertib when administered in combination with KRASG12C inhibitors sotorasib or adagrasib.
  • The data demonstrated synergistic cell growth inhibition across a panel of KRASG12C cell lines in both 2D and 3D assays.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Survival, Survival rate, NSCLC, Associate, Cervical cancer, Medicine, Patient, Lung, University, MD, Lung cancer, AACR, University of Southern California, Vaccine

The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.

Key Points: 
  • The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
  • Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
  • “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types.
  • “This promising preclinical data presented at AACR 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors.”

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Retrieved on: 
Wednesday, March 13, 2024
Therapy, FDA, Patent, Bile, Spacecraft, Lung, GLP, Breast, Reactive oxygen species, Patient, Survival, Cell death, Melanoma, Pharmaceutical industry

DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Key Points: 
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no.
  • 11,890,350 (‘350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
  • This patent marks the fourth granted US patent in Defence’s ever-growing patent portfolio, which currently incudes seven published patent families.

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
SAN, 23andMe, FDA, Cancer, AACR, Therapy, Genetics, NK, NKG2D, Cell death, Biology, IND, Vaccine

These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.

Key Points: 
  • These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 5, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation